Pfizer announced Thursday that it elected former FDA commissioner Scott Gottlieb to its board of directors, effective immediately. Ian Read, executive chairman at Pfizer, remarked that "we are fortunate to have Gottlieb join Pfizer's board," adding that his "expertise in healthcare, public policy and the industry will be an asset to our company."
Gottlieb, who was also appointed to the regulatory and compliance committee and the science and technology committee of Pfizer's board, is currently a special partner of New Enterprise Associations' healthcare investment team and a resident fellow of the American Enterprise Institute.
Albert Bourla, chief executive at Pfizer, said that "through his work as a physician and his time at the FDA, [Gottlieb] has continually demonstrated an understanding of both patients' needs and the rapidly changing dynamics of biopharmaceutical R&D." Last October, Pfizer announced a shake up  to its management team in the lead up to Bourla taking over as CEO of the company at the start of this year.